{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:31:58Z","timestamp":1772775118860,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea government Ministry of Science and ICT","award":["2019-0-00224"],"award-info":[{"award-number":["2019-0-00224"]}]},{"DOI":"10.13039\/501100003725","name":"The National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2024-00461071"],"award-info":[{"award-number":["RS-2024-00461071"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Korea government Ministry of Science and ICT","award":["2710008830"],"award-info":[{"award-number":["2710008830"]}]},{"DOI":"10.13039\/501100003725","name":"The National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2025-00523629"],"award-info":[{"award-number":["RS-2025-00523629"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec019\">\n<jats:title>Background<\/jats:title>\n<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major risk factor for liver cirrhosis, yet effective prevention or treatment strategies remain limited. To address this, we utilized a signature-based in silico drug repositioning approach to identify potential therapeutics for MASLD that may reduce the risk of cirrhosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We analyzed gene expression datasets to identify differentially expressed genes (DEGs) in MASLD and matched them to candidate drugs using L1000CDS2. We further validated potential drugs by cross-referencing with prescription data from the Korea National Health Insurance Service (NHIS). Participants who underwent health screenings between 2013 and 2014 were included. MASLD was diagnosed in individuals with hepatic steatosis (fatty liver index \u226560) and at least one cardiometabolic risk factor.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec021\">\n<jats:title>Results<\/jats:title>\n<jats:p>We identified 11 drug candidates and analyzed 49,555 MASLD patients (mean age: 63.0 years, SD: 8.6). Atenolol (SHR: 0.81; 95% CI: 0.72\u20130.92; P\u2009&lt;\u20090.001), isosorbide dinitrate (SHR: 0.82; 95% CI: 0.73\u20130.93; P\u2009=\u20090.001), and valsartan (SHR: 0.52; 95% CI: 0.45\u20130.60; P\u2009&lt;\u20090.001) were associated with a reduced risk of cirrhosis. Conversely, amlodipine-based combinations (SHR: 1.24; 95% CI: 1.11\u20131.39; P\u2009&lt;\u20090.001), torasemide (SHR: 1.39; 95% CI: 1.24\u20131.56; P\u2009&lt;\u20090.001), and valsartan-based combinations (SHR: 1.22; 95% CI: 1.09\u20131.37; P\u2009&lt;\u20090.001) were linked to an increased risk.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec022\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our findings suggest that antihypertensive drugs such as atenolol and isosorbide dinitrate may protect MASLD patients from cirrhosis, providing valuable insights for clinical applications and treatment strategies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec023\">\n<jats:title>Limitations<\/jats:title>\n<jats:p>This study is limited to drugs registered in the Korean NHIS, potentially excluding other relevant candidates. Additionally, the absence of dietary and genetic data in the NHIS database may introduce residual confounding. Lastly, as the study population consists solely of Korean adults, the findings may not be generalizable to other populations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0323880","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:02:41Z","timestamp":1749060161000},"page":"e0323880","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-8230","authenticated-orcid":true,"given":"Chae Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seogsong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Wook","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"9","key":"pone.0323880.ref001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"K Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10290","key":"pone.0323880.ref002","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"EE Powell","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"pone.0323880.ref003","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Z Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"pone.0323880.ref004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3350\/cmh.2024.0145","article-title":"Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study","volume":"30","author":"S Jeong","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"44","key":"pone.0323880.ref005","article-title":"Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean","volume":"102","author":"YH Oh","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pone.0323880.ref006","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3350\/cmh.2023.0129","article-title":"Letter regarding \u201cNon-alcoholic fatty liver disease: Definition and subtypes\u201d","volume":"29","author":"S Jeong","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"pone.0323880.ref007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.31083\/j.rcm2406173","article-title":"Non-alcoholic fatty liver disease, atherosclerosis, and cardiovascular disease in Asia","volume":"24","author":"Y Lim","year":"2023","journal-title":"Rev Cardiovasc Med"},{"issue":"6","key":"pone.0323880.ref008","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0323880.ref009","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"key":"pone.0323880.ref010","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study","volume":"65","author":"JH Moon","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"pone.0323880.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.09.013","article-title":"Nutrients associated with metabolic dysfunction-associated steatotic liver disease","volume":"80","author":"S Jeong","year":"2024","journal-title":"J Hepatol"},{"issue":"8","key":"pone.0323880.ref012","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"BL Clifford","year":"2021","journal-title":"Cell Metab"},{"issue":"4","key":"pone.0323880.ref013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000535943","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: a korean nationwide study","volume":"13","author":"G-A Kim","year":"2023","journal-title":"Liver Cancer"},{"key":"pone.0323880.ref014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","article-title":"The gene expression omnibus database","volume":"1418","author":"E Clough","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"4","key":"pone.0323880.ref015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/1566523220666201012151803","article-title":"A five-gene signature for predicting the prognosis of colorectal cancer","volume":"21","author":"J Hong","year":"2021","journal-title":"Curr Gene Ther"},{"key":"pone.0323880.ref016","doi-asserted-by":"crossref","DOI":"10.1038\/npjsba.2016.15","article-title":"L1000CDS2: LINCS L1000 characteristic direction signatures search engine","volume":"2","author":"Q Duan","year":"2016","journal-title":"NPJ Syst Biol Appl"},{"issue":"1","key":"pone.0323880.ref017","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1038\/s41598-024-55870-4","article-title":"Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data","volume":"14","author":"F Meiners","year":"2024","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0323880.ref018","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165024","article-title":"Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis","volume":"8","author":"D Papadopoulou","year":"2023","journal-title":"JCI Insight"},{"key":"pone.0323880.ref019","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank Knowledgebase for 2024","volume":"52","author":"C Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"pone.0323880.ref020","first-page":"799","article-title":"Data resource profile: The national health information database of the national health insurance service in South Korea","volume":"46","author":"S CheolSeong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"pone.0323880.ref021","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/hepr.14115","article-title":"Association between antibiotic use and cardiovascular diseases in metabolic dysfunction-associated steatotic liver disease: a nationally representative retrospective cohort study","volume":"55","author":"J Kang","year":"2025","journal-title":"Hepatol Res"},{"issue":"2","key":"pone.0323880.ref022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7570\/jomes22024","article-title":"Obesity Fact Sheet in Korea, 2021: Trends in Obesity Prevalence and Obesity-Related Comorbidity Incidence Stratified by Age from 2009 to 2019","volume":"31","author":"Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity","year":"2022","journal-title":"J Obes Metab Syndr"},{"issue":"12","key":"pone.0323880.ref023","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"V Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"pone.0323880.ref024","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.amjmed.2019.05.012","article-title":"Digoxin use and outcomes in patients with heart failure with reduced ejection fraction","volume":"132","author":"SZ Qamer","year":"2019","journal-title":"Am J Med"},{"issue":"3","key":"pone.0323880.ref025","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial","volume":"3","author":"M Holmer","year":"2021","journal-title":"JHEP Rep"},{"issue":"13","key":"pone.0323880.ref026","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.3748\/wjg.v21.i13.3777","article-title":"Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"21","author":"Y Takahashi","year":"2015","journal-title":"World J Gastroenterol"},{"key":"pone.0323880.ref027","article-title":"Atenolol","volume-title":"StatPearls","author":"B Rehman","year":"2024"},{"issue":"3","key":"pone.0323880.ref028","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3904\/kjim.2004.19.3.165","article-title":"Relationship of hemodynamic indices and prognosis in patients with liver cirrhosis","volume":"19","author":"SK Baik","year":"2004","journal-title":"Korean J Intern Med"},{"issue":"5","key":"pone.0323880.ref029","first-page":"209","article-title":"Korean j gastroenterol","volume":"82","author":"S Jo","year":"2023","journal-title":"Korean J Gastroenterol"},{"issue":"2","key":"pone.0323880.ref030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2021.09.029","article-title":"Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?","volume":"76","author":"G Baffy","year":"2022","journal-title":"J Hepatol"},{"key":"pone.0323880.ref031","article-title":"Isosorbide","volume-title":"StatPearls","author":"S Balasubramanian","year":"2023"},{"issue":"1","key":"pone.0323880.ref032","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000056066","article-title":"Effect of isosorbide dinitrate on nitric oxide synthase under hypoxia","volume":"62","author":"HB Jiang","year":"2001","journal-title":"Pharmacology"},{"issue":"3","key":"pone.0323880.ref033","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0168-8278(89)90029-9","article-title":"Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension","volume":"8","author":"P Mols","year":"1989","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0323880.ref034","doi-asserted-by":"crossref","first-page":"979","DOI":"10.14218\/JCTH.2021.00593","article-title":"Portal hypertension in nonalcoholic fatty liver disease: from pathogenesis to clinical practice","volume":"10","author":"SHH Nababan","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"pone.0323880.ref035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1185\/03007990903533681","article-title":"Effects of beta-blockers on glucose and lipid metabolism","volume":"26","author":"VA Fonseca","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"pone.0323880.ref036","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"M Eslam","year":"2020","journal-title":"J Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:02:53Z","timestamp":1749060173000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323880"}},"subtitle":[],"editor":[{"given":"Samuel O.","family":"Antwi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323880","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}